Key result
P-selectin indicates platelet activation across coronary artery disease, stroke, diabetes, and malignancy.
Answers are grounded in this paper and cite their sources.
Activated platelets are key components in many arterial disorders. P-selectin is an activation-dependent platelet receptor, which is also identified in endothelial cells. Together with E- and L-selectin it constitutes the selectin family. These transmembrane proteins have continued to attract great interest as they support rapid and reversible cell adhesion in flow systems and thus play an essential role in multicellular interactions during thrombosis and inflammation. Similarly to other lectins, selectins bind to different glycoconjugates with varying affinities. Protein ligands, equipped with the appropriate carbohydrate and sulfate moieties for P-selectin binding, have been identified in normal peripheral blood leukocytes and several non-hematopoietic organs, as well as on cancer cells. For diagnostic purposes, P-selectin can readily be detected on the platelet surface by flow cytometry and by ELISA as a soluble ligand in the plasma. Along with other markers, these data can be used in the assessment of platelet activation status. Such results bear clinical significance since P-selectin has been implicated in the pathogenesis of wide-spread disorders including coronary artery disease, stroke, diabetes and malignancy.
No takes yet. Share an insight, caveat, or question.
Kappelmayer et al. (2004) conducted a review in Arterial disorders, coronary artery disease, stroke, diabetes, and malignancy. P-selectin (platelet surface or soluble plasma biomarker) was evaluated. P-selectin detected via flow cytometry or ELISA serves as a clinical marker of platelet activation implicated in coronary artery disease, stroke, diabetes, and malignancy.
Synapse has enriched 10 related papers. Consider them for comparative context: